LDLR and inflammatory bowel disease: In contrast, genetically proxied LPL enhancement was significantly associated with a lower risk of IBD and CD (OR = 0.772, P-adjusted = 0.012; OR = 0.661, P-adjusted = 0.003, respectively), so as genetically proxied LDLR enhancement (OR = 0.786, P-adjusted = 0.044; OR = 0.718, P-adjusted = 0.044, respectively).